Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease

June 15 (Reuters) - Johnson & Johnson JNJ.N:

• INVESTIGATIONAL COMBINATION OF FIRST-IN-CLASS BISPECIFICS TALVEY® AND TECVAYLI® SHOWS DEEP AND DURABLE RESPONSES IN HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE

• JOHNSON & JOHNSON - PHASE 2 STUDY SHOWS 78.9% OVERALL RESPONSE RATE

• JOHNSON & JOHNSON - NOVEL APPROACH SHOWS POTENTIAL IN EXTRAMEDULLARY DISEASE PATIENTS

• JOHNSON & JOHNSON - COMBINATION THERAPY ACHIEVES 78.9% ORR, 54.4% COMPLETE RESPONSE

• JOHNSON & JOHNSON - 61% OF PATIENTS PROGRESSION FREE AND ALIVE AT ONE YEAR

• JOHNSON & JOHNSON - 64.1% MAINTAIN RESPONSE, 74.5% ALIVE AT ONE YEAR